I don't want to further cry over spilt milk but I still don't understand how a prudent board/management team stuffs up clinical trials so badly. Surely when you are engaging in a make/break regulatory outcome which is so serious for the future of the company you exercise due conservatism and caution and deliver quality clinical data. You learn in high school science that you need to provide a double-blind study with comparisons to baselines for heavens sake. It makes me very cross indeed or very suspicious that they were unduly concerned that the product actually doesn't have much benefit compared to standard care protocols. There's only two possible outcomes, either the previous management team were incompetent and not sufficiently risk cautious or not very confident in the technology and its clinical outcomes.
TIS Price at posting:
4.7¢ Sentiment: Hold Disclosure: Held
